https://www.selleckchem.com/pr....oducts/gsk2126458.ht
Vascular invasion was present in 60.5% and median was HVPG 8.5 mm Hg. No significant modification in HVPG and EV size was observed at 6months in the whole cohort but also when considering vascular invasion and radiological response. 14% presented AVB within a median time of occurrence of 3months, without bleeding-related death. In multivariate analysis, history of AVB (HR=10.58, p= .03) was associated with AVB. AVB incidence was higher in atezolizumab-bevacizumab compared to sorafenib group (21% vs. 5% at 1 year, p= .02). Atezolizuma
Like
Comment
Share
